Last10K.com

Checkmate Pharmaceuticals, Inc. (CMPI) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

Checkmate Pharmaceuticals, Inc.

CIK: 1651431 Ticker: CMPI
Cover Page - USD ($)
12 Months Ended
Dec. 31, 2020
Mar. 29, 2021
Document Information [Line Items]  
Document Type10-K 
Amendment Flagfalse 
Document Period End DateDec. 31, 2020 
Document Fiscal Year Focus2020 
Document Fiscal Period FocusFY 
Document Annual Reporttrue 
Document Transition Reportfalse 
Entity Interactive Data CurrentYes 
Entity Registrant NameCheckmate Pharmaceuticals, Inc. 
Entity Central Index Key0001651431 
Current Fiscal Year End Date--12-31 
Entity Current Reporting StatusYes 
Entity Well-known Seasoned IssuerNo 
Entity Voluntary FilersNo 
Entity Shell Companyfalse 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companytrue 
Entity Ex Transition Periodfalse 
Entity Incorporation, State or Country CodeDE 
Entity Address, State or ProvinceDE 
Entity Address, CountryMA 
Title of 12(b) SecurityCommon Stock 
Trading SymbolCMPI 
Security Exchange NameNASDAQ 
Entity Public Float$ 314,566,207 
Entity Common Stock, Shares Outstanding 21,618,395
ICFR Auditor Attestation Flagfalse 

View differences made from one year to another to evaluate Checkmate Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Checkmate Pharmaceuticals, Inc..

Continue

Assess how Checkmate Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Checkmate Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Legal
Revenue
Other
Filter Subcategory:
All
Expense
Cash Flow
Product
Shares
Other
Inside Checkmate Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' (Deficit)
Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' (Deficit) (Parenthetical)
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Schedule Of Accrued Expenses (Detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Common Stock
Convertible Notes
Convertible Notes - Additional Information (Detail)
Defined Contribution Plan
Defined Contribution Plan - Additional Information (Detail)
Fair Value Measurement
Fair Value Measurement (Tables)
Fair Value Measurement - Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Components Of Company Deferred Tax Assets (Detail)
Income Taxes - Schedule Of Reconciliation Of U.S. Federal Statutory Income Tax Rate And Effective Income Tax Rate (Detail)
Income Taxes - Summary Of Unrecognized Benefits (Detail)
Investments
Investments (Tables)
Investments - Additional Information (Detail)
Investments - Summary Of Amortized Cost And Estimated Fair Value Company's&Amp;#160;Available For Sale&Amp;#160;Investments (Detail)
Investments - Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity (Detail)
Nature Of Business
Nature Of Business - Additional Information (Detail)
Net Loss Per Share Attributable To Common Stockholders
Net Loss Per Share Attributable To Common Stockholders (Tables)
Net Loss Per Share Attributable To Common Stockholders - Summary Of Potentially Dilutive Shares Excluded From The Calculation Of Diluted Net Loss (Detail)
Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock (Tables)
Redeemable Convertible Preferred Stock - Additional Information (Detail)
Redeemable Convertible Preferred Stock - Schedule Of Redeemable Convertible Preferred Stock (Detail)
Stock Based Compensation
Stock Based Compensation - (Tables)
Stock Based Compensation - Additional Information (Detail)
Stock Based Compensation - Schedule Of Fair Value Of Stock Option Awards On The Grant Date Using The Black-Scholes Option Valuation Model (Detail)
Stock Based Compensation - Summary Of Total Stock-Based Compensation Expense (Details)
Stock Based Compensation - Summary The Activity Under The Company's Stock Option Plan (Detail)
Subsequent Events
Subsequent Events - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies -Additional Information (Detail)
Valuation Of Series B Preferred Stock Tranche Right Liability
Valuation Of Series B Preferred Stock Tranche Right Liability (Tables)
Valuation Of Series B Preferred Stock Tranche Right Liability - Additional Information (Detail)
Valuation Of Series B Preferred Stock Tranche Right Liability - Schedule Of Aggregate Fair Value Of The Company's Series B Preferred Stock Tranche Right Liability (Detail)
Valuation Of Series B Preferred Stock Tranche Right Liability - Schedule Of Fair Value, Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation (Detail)
Ticker: CMPI
CIK: 1651431
Form Type: 10-K Annual Report
Accession Number: 0001193125-21-098414
Submitted to the SEC: Mon Mar 29 2021 4:52:25 PM EST
Accepted by the SEC: Mon Mar 29 2021
Period: Thursday, December 31, 2020
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/cmpi/0001193125-21-098414.htm